Health Catalyst Inc. (NASDAQ:HCAT) Relative Strength Index (RSI) is 50.19, with weekly volatility at 3.99% and ATR at 2.13. The HCAT stock’s 52-week price range has touched low of $25.68 and a $59.10 high. Intraday shares traded counted 0.36 million, which was 27.73% higher than its 30-day average trading volume of 500.87K. Its shares traded higher over the last trading session, gaining 1.98% on 05/20/21. The shares fell to a low of $50.02 before closing at $51.09. HCAT’s previous close was $50.10 while the outstanding shares total 43.87M.
Investors have identified the Health Information Services company Health Catalyst Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.25 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Health Catalyst Inc. (HCAT) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 324.74 million total, with 259.43 million as their total liabilities.
HCAT were able to record -9.91 million as free cash flow during the 08/26/2021 quarter of the year, this saw their quarterly net cash flow reduce by 40.67 million. In cash movements, the company had a total of -3.14 million as operating cash flow.
Potential earnings growth for Health Catalyst Inc. (HCAT)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/26/2021 quarter of the year, Health Catalyst Inc. recorded a total of 55.85 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 19.21% coming in sequential stages and their sales for the 08/26/2021 quarter increasing by 4.6%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 27.34 million trying to sell their products during the last quarter, with the result yielding a gross income of 28.51 million. This allows shareholders to hold on to 43.87M with the recently reported earning now reading -0.65 cents per share. This is a figure that compared to analyst’s prediction for their 08/26/2021 (-0.37 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.13 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on HCAT sounds very interesting.
Is the stock of HCAT attractive?
In related news, President, Nelli James Patrick Jr. sold 14,804 shares of the company’s stock in a transaction that recorded on May 11. The sale was performed at an average price of 49.68, for a total value of 735,482. As the sale deal closes, the Chief Operating Officer, Horstmeier Paul now sold 9,836 shares of the company’s stock, valued at 540,375. Also, Chief People Officer, Llewelyn Linda sold 3,455 shares of the company’s stock in a deal that was recorded on May 03. The shares were price at an average price of 58.10 per share, with a total market value of 200,743. Following this completion of acquisition, the General Counsel, Orenstein Daniel H. now holds 3,500 shares of the company’s stock, valued at 179,494. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.10%.
15 out of 15 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Health Catalyst Inc.. 0 analysts has assigned a Sell rating on the HCAT stock. The 12-month mean consensus price target for the company’s shares has been set at $54.77.